| NCT Number | NCT06208878 |
| Lead Sponsor | CRISPR Therapeutics AG |
| Conditions | Hematologic Malignancy, Solid Malignancy |
| Enrollment | 70 participants |
| Start Date | 2023-11-22 |
| Primary Completion | 2038-08 (estimated) |
| Study Completion | 2038-08 (estimated) |
| Updated on ClinicalTrials.gov | 2025-08-14 |